Summary
- Current Price
- As of today, LCTX price is $1.31, down -4.38% on
- Current Price All-Time High
- LCTX price is currently -95.15% below its historical high of $27.00 set on
- Market Cap
- LCTX current market cap is $327M, up +197.95% over the past 365 days
- PE Ratio
- LCTX PE ratio is unknown
- Revenue
- LCTX current annual revenue is $14.56M, up +53.24% year-over-year
- Next Earnings
- The next earnings release for LCTX is on
Profile
| Metric | Value |
|---|---|
| Full Name | Lineage Cell Therapeutics, Inc. |
| Ticker | NYSEAmerican: LCTX |
| Exchange | NYSE American |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | lineagecell.com |
| Employees | 70 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| $1.31 | ||
| Price, 1D Change | -4.38% | |
| $327M | ||
| - | ||
| - | ||
| 1.51 | ||
| $15M | ||
| Revenue, 1Y Change | +53.24% | |
| -$0.28 | ||
| EPS, 1Y Change | -196.88% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 3:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | BTX | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| -$0.28 | ||
| EPS Estimate | N/A | -$0.09 |
| EPS Est. Change | N/A | +68.31% |
| $14.56M | ||
| Revenue Estimate | N/A | $20.50M |
| Revenue Est. Change | N/A | +40.83% |
| $1.31 | ||
| Price Target | - | $4.00 |
| Price Tgt. Change | - | +205.34% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.11 | -$0.09 | +15.45% | |
| -$0.29 | -$0.28 | +4.23% | |
| -$0.09 | N/A | +68.31% | |
| -$0.08 | N/A | +71.93% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $8.25M | $9.50M | +15.09% | |
| $9.90M | $14.56M | +47.01% | |
| $20.50M | N/A | +40.83% | |
| $20.39M | N/A | +40.09% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| +172.92% | ||
| -5.07% | ||
| +197.95% | ||
| +39.07% | ||
| +53.24% | ||
| -1.00% | ||
| -196.88% | ||
| -78.47% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| $1.31 | ||
| $1.58 | ||
| SMA 200 vs Price | +20.24% | |
| $1.58 | ||
| SMA 50 vs Price | +20.60% | |
| 1.51 | ||
| $0.09 | ||
| 31.90 | ||
| 60.32% | ||
| 72.67% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| $14.56M | ||
| -$0.28 | ||
| $13.71M | ||
| 94.19% | ||
| -$21.78M | ||
| -149.62% | ||
| -$63.37M | ||
| -435.33% | ||
| -$21.08M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| 0.05 | ||
| 5.20 | ||
| 5.20 | ||
| - | ||
| 4 | ||
| -2.98 |
Valuations
| Metric | Date | Value |
|---|---|---|
| - | ||
| 22.44 | ||
| 7.33 | ||
| -12.96 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| $44.55M | ||
| $55.78M | ||
| $112.58M | ||
| $59.16M | ||
| $69.24M | ||
| $11.37M | ||
| $2.42M | ||
| $853.00K | ||
| $2.34M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $78.09M | ||
| $35.49M | ||
| $845.00K | ||
| $0.00 | ||
| $699.00K | ||
| $0.00 | ||
| -$5.28M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$18.92M | ||
| -$13.46M | ||
| $26.95M | ||
| $522.00K | ||
| -$19.44M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| D. Boral Capital | → | |
| Canaccord Genuity | ||
| B. Riley Securities | → | |
| HC Wainwright & Co. | → | |
| D. Boral Capital | → | |
| D. Boral Capital | → | |
| D. Boral Capital | → | |
| HC Wainwright & Co. | → | |
| D. Boral Capital | → | |
| D. Boral Capital | → |
Analyst sentiment
Institutional ownership
Screeners with LCTX
FAQ
What is the ticker symbol for Lineage Cell Therapeutics, Inc.?
The ticker symbol for Lineage Cell Therapeutics, Inc. is NYSEAmerican:LCTX
Does Lineage Cell Therapeutics, Inc. pay dividends?
No, Lineage Cell Therapeutics, Inc. does not pay dividends
What sector is Lineage Cell Therapeutics, Inc. in?
Lineage Cell Therapeutics, Inc. is in the Healthcare sector
What industry is Lineage Cell Therapeutics, Inc. in?
Lineage Cell Therapeutics, Inc. is in the Biotechnology industry
What country is Lineage Cell Therapeutics, Inc. based in?
Lineage Cell Therapeutics, Inc. is headquartered in United States
When did Lineage Cell Therapeutics, Inc. go public?
Lineage Cell Therapeutics, Inc. initial public offering (IPO) was on March 5, 1992
Is Lineage Cell Therapeutics, Inc. in the S&P 500?
No, Lineage Cell Therapeutics, Inc. is not included in the S&P 500 index
Is Lineage Cell Therapeutics, Inc. in the NASDAQ 100?
No, Lineage Cell Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Lineage Cell Therapeutics, Inc. in the Dow Jones?
No, Lineage Cell Therapeutics, Inc. is not included in the Dow Jones index
When was Lineage Cell Therapeutics, Inc. last earnings report?
Lineage Cell Therapeutics, Inc.'s most recent earnings report was on March 5, 2026
When does Lineage Cell Therapeutics, Inc. report earnings?
The next expected earnings date for Lineage Cell Therapeutics, Inc. is May 12, 2026
Data Sources & References
- LCTX Official Website www.lineagecell.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/876343/000119312526093992/0001193125-26-093992-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/876343/000119312526093992/0001193125-26-093992-index.htm
- LCTX Profile on Yahoo Finance finance.yahoo.com/quote/LCTX
- LCTX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/lctx